Small bowel neuroendocrine tumors (SBNETs) have been increasing in frequency over the
past decades, and are now the most common type of small bowel tumor. Consequently …

Nuclear medicine is composed of two complementary areas, imaging and therapy. Positron
emission tomography (PET) and single-photon imaging, including single-photon emission …

Somatostatin receptor (SSTR) PET has demonstrated a significant improvement over
conventional imaging (CI) in patients with neuroendocrine tumors (NETs). SSTR PET should …

Somatostatin, also known as somatotropin-release inhibitory factor, is a cyclopeptide that
exerts potent inhibitory actions on hormone secretion and neuronal excitability. Its …

Nanomaterials offer new opportunities for cancer diagnosis and treatment. Multifunctional
nanoparticles harboring various functions including targeting, imaging, therapy, and etc …

Somatostatin receptor (sstr) scintigraphy for imaging and sstr analogs for treatment have
been used for more than 20 y. An important improvement in recent years was the …

Somatostatin is a peptide with a potent and broad antisecretory action, which makes it an
invaluable drug target for the pharmacological management of pituitary adenomas and …

OBJECTIVE. The purpose of this article is to provide a review of the use of 68Ga
tetraazacyclododecanetetraacetic acid–DPhe1-Tyr3-octreotate (DOTATATE) PET/CT, a …

The aim of these guidelines is to assist nuclear medicine physicians in recommending,
performing, reporting and interpreting the results of somatostatin (SST) receptor PET/CT …

Selective receptor-targeting peptide based agents have attracted considerable attention in
molecular imaging of tumor cells that overexpress corresponding peptide receptors due to …